Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Neutral
- Symbol (ARNA)
- Company Arena Pharmaceuticals, Inc.
- Price $99.99
- Changes Percentage (0%)
- Change -$0
- Day Low $99.97
- Day High $100.00
- Year High $100.00
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/04/2022
- Fiscal Year End N/A
- Average Stock Price Target $92.00
- High Stock Price Target $100.00
- Low Stock Price Target $90.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$10.14
- Trailing P/E Ratio -9.8580301685892
- Forward P/E Ratio -9.8580301685892
- P/E Growth -9.8580301685892
- Net Income $-620,592,000
Income Statement
Quarterly
Annual
Latest News of ARNA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
LVMH's Bernard Arnault set to overtake Mark Zuckerberg as the world's 3rd-richest person after $24 billion wealth surge
Bernard Arnault's fortune surged by $24 billion in four days, driven by LVMH's stock rise and its stake in Moncler. He is set to surpass Mark Zuckerberg as the world's third-richest person....
By Yahoo! Finance | 2 days ago -
Parnassus Value Equity Fund Sold Cisco Systems (CSCO) for More Attractive Opportunity
Parnassus Investments released the Q2 2024 investor letter for the Parnassus Value Equity Fund, reporting a -3.81% return. Highlighting Cisco Systems, Inc. as a stock pick, the firm believes in AI-rel...
By Yahoo! Finance | 4 days ago -
Klarna partners with fellow fintech Adyen to bring buy now, pay later into physical stores
Klarna plans to be profitable by summer 2023 and is teaming up with Adyen to introduce its buy now, pay later service in physical stores. The partnership will initially launch in Europe, North America...
By CNBC | 4 days ago
